0001209191-18-026542.txt : 20180427 0001209191-18-026542.hdr.sgml : 20180427 20180427160929 ACCESSION NUMBER: 0001209191-18-026542 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180426 FILED AS OF DATE: 20180427 DATE AS OF CHANGE: 20180427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CARLSON MARILYN R. CENTRAL INDEX KEY: 0001592848 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36075 FILM NUMBER: 18783925 MAIL ADDRESS: STREET 1: C/O EVOKE PHARMA, INC. STREET 2: 505 LOMAS SANTA FE DRIVE CITY: SOLANA BEACH STATE: CA ZIP: 92075 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evoke Pharma Inc CENTRAL INDEX KEY: 0001403708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208447886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-345-1494 MAIL ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-04-26 0 0001403708 Evoke Pharma Inc EVOK 0001592848 CARLSON MARILYN R. C/O EVOKE PHARMA, INC. 420 STEVENS AVENUE, SUITE 370 SOLANA BEACH CA 92075 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 2.43 2018-04-26 4 A 0 125000 0.00 A 2028-02-06 Common Stock 125000 125000 D The option grant date was February 7, 2018, subject to approval of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "Plan") by the Issuer's stockholders which occurred at the Issuer's annual stockholder meeting on April 26, 2018. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2018, subject to the reporting person's continued service to the Issuer through each such vesting date. Notwithstanding the foregoing vesting schedule, in no event may the option be exercised prior to the earlier of (i) the date on which the Issuer receives marketing approval from the U.S. Food and Drug Administration of Gimoti, (ii) the second anniversary of the date of grant, or (iii) the date of a "change in control" under Section 2.9 of the Plan. /s/ Matthew J. D'Onofrio, Attorney-in-fact for Marilyn R. Carlson 2018-04-27